Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound. Disclaimer

LimitlessLab
Search the library Wishlist Cart, items: 0
ARA-290

Recovery & Healing

ARA-290

Also known as Cibinetide, Helix B Surface Peptide, HBSP, ARA290

Moderate human evidenceIn clinical trialsWADA prohibited

Price range: €30 through €59

Discussed for: Nerve pain, inflammation, tissue repair.

Sequence: not listed. Modified or non-standard residues are left out on purpose.

Effect strengthHow hard it acts on the body4/10
Proof levelHow well that is shown in humans5/10
Risk levelHow much can go wrong3/10

Editorial 1 to 10 estimates from published research, not measured values. How to read these

Save to wishlist
Save to wishlist

01 / Identity

What it is

ARA-290 is a synthetic peptide (11 aa, from erythropoietin). Main reported uses: nerve pain, inflammation, tissue repair. Current status: not approved, orphan designation, Phase 2 completed.

Molecule type
Synthetic peptide (11 aa, from erythropoietin)
How it is taken
Injection (SC)
Other names
Cibinetide, Helix B Surface Peptide, HBSP, ARA290

Route only. This library does not publish doses or protocols.

02 / Mechanism

How it is thought to work

Activates the innate repair receptor (EPO receptor + CD131) without raising red blood cells

03 / Potential benefits

What people use it for

Nerve pain, inflammation, tissue repair

Moderate human evidence

Some human trials exist, but they are smaller, shorter or mixed.

Listed uses are what people use it for, not proven outcomes.

04 / Known risks

Side effects and risks

Injection-site reactions; long-term safety unknown

Risk level 3 of 10

Lower risk score: reported side effects are mostly mild. Low risk is not no risk, especially for unregulated products.

Unknown long-term effects count as a risk, not as a clean record.

05 / Regulatory

Regulatory status

Status
In clinical trials
Details
Not approved, orphan designation, Phase 2 completed
Sport (WADA)
Yes: S0 (unapproved substance)

Status reflects information up to mid-2026 and changes over time. Check current sources.

06 / Evidence quality

How good is the evidence?

Moderate: Phase 2 human trials in sarcoidosis small-fibre neuropathy

How we grade evidence

07 / Notes and sources

Notes and sources

  • Products sold online as research peptides are unregulated. Tests of such products often find wrong amounts, impurities or a different compound.
  • Anyone using compounds like this regularly should have medical supervision and bloodwork (for example IGF-1, glucose and HbA1c, hormones, lipids).
  • Source: Peptide Reference Table, an editorial review of published research up to mid-2026. Scores are 1 to 10 editorial estimates, not measured values. Regulatory and WADA status change over time.

Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound.

Related compounds